The presence of additional mutations in the TET2, ASXL1, DNMT3A, IDH, and EZH2 genes in PV and ET patients was associated with failure to achieve a complete molecular response during treatment with pegylated interferon alpha (Quintás-Cardama et al., 2013). This evidence concerns the gene DNMT3A and essential thrombocythemia.